Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2098-2105

  Li, Chi Chung ^a   Sun, Peng ^a   Dong, Yingwen ^a   Bi, Sheng ^a   Desai, Rajesh ^a   Dockendorf, Marissa Fallon ^a,b   Kartsonis, Nicholas A ^a   Ngai, Angela L ^a   Bradshaw, Susan ^a   Stone, Julie A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Vistakon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; DEXAMETHASONE; SERUM ALBUMIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BODY SURFACE; BODY WEIGHT; CANDIDIASIS; CHILD; CONTROLLED STUDY; DISEASE COURSE; DRUG EXPOSURE; FEVER; GROUPS BY AGE; HUMAN; INFANT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; HUMANS; INFANT; MALE; MYCOSES; PROSPECTIVE STUDIES;

EID: 79955535490     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00905-10     Document Type: Article

References (33)

1. Abbasi, S., J. L. Shenep, W. T. Hughes, and P. M. Flynn. 1999. Aspergillosis in children with cancer: a 34-year experience. Clin. Infect. Dis. 29:1210-1219.
2. Arathoon, E. G., et al. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.
3. Betts, R., et al. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin. Infect. Dis. 48:1676-1684.
4. Bi, S., M. S. Schwartz, R. B. Desai, A. R. Miller, and B. K. Matuszewski. 2005. A semi-automated procedure for the determination of caspofungin in human plasma using solid-phase extraction and HPLC with fluorescence detection using secondary ionic interactions to obtain a highly purified extract. J. Liq. Chromatogr. Related Technol. 28:2895-2908.
5. Chanock, S. J., and T. J. Walsh. 1996. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transplant. 18(Suppl. 3):S15-S20.
6. Reference deleted.
7. Engelhard, D. 1998. Bacterial and fungal infections in children undergoing bone marrow transplantation. Bone Marrow Transplant. 21(Suppl. 2):S78-S80. (Pubitemid 28223363)
8. Hope, W. W., et al. 2007. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51:3714-3719.
9. Kartsonis, N. A., J. Nielsen, and C. M. Douglas. 2003. Caspofungin: the first in a new class of antifungal agents. Drug Resist. Updat. 6:197-218.
10. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358-366.
11. Maertens, J. A., et al. 2010. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr. Infect. Dis. J. 29:415-420.
12. Maertens, J., et al. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39:1563-1571.
13. Merck & Co., Inc. 2008. Cancidas (caspofungin acetate) for injection, prescribing information, July. Merck & Co., Inc., Whitehouse Station, NJ.
14. Migoya, E., et al. 2011. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult subjects. J. Clin. Pharmacol. 51:202-211.
15. Mora-Duarte, J., et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
16. Neely, M., et al. 2009. The pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob. Agents Chemother. 53:1450-1456.
17. Pappas, P. G., et al. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
18. Rodriguez-Nunez, A. 2001. Incidence and mortality of proven invasive Candida infections in pediatric intensive care patients. Infect. Control Hosp. Epidemiol. 22:477-478.
19. Sable, C. A., B.-Y. T. Nguyen, J. A. Chodakewitz, and M. J. DiNubile. 2002. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. 4:25-30.
20. Schwartz, M., W. Kline, and B. Matuszewski. 1997. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal. Chem. Acta 352:299-307.
21. Segal, B. H., et al. 2008. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis. 47:674-683.
22. Shetty, D., N. Giri, C. E. Gonzalez, P. A. Pizzo, and T. J. Walsh. 1997. Invasive aspergillosis in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 16:216-221.
23. Stone, J. A., et al. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
24. Stone, J., et al. 2003. Population pharmacokinetics of caspofungin in candidiasis patients, abstr. A-1571. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
25. Stone, J., et al. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. 48:4306-4314.
26. Villaneuva, A., et al. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535.
27. Villaneuva, A., et al. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-299.
28. Walmsley, S., et al. 1993. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediatr. Infect. Dis. J. 12:673-682.
29. Walsh, T. J., et al. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49: 4536-4545.
30. Walsh, T. J., et al. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.
31. Zaoutis, T. 2010. Candidemia in children. Curr. Med. Res. Opin. 26:1761-1768.
32. Zaoutis, T. E., et al. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41:1232-1239.
33. Zaoutis, T. E., et al. 2009. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123:877-884.